Lead optimization of Novel mGlu2 Negative Allosteric Modulators
新型 mGlu2 负变构调节剂的先导化合物优化
基本信息
- 批准号:9251915
- 负责人:
- 金额:$ 78.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2019-01-31
- 项目状态:已结题
- 来源:
- 关键词:AMPA ReceptorsAcidsAddressAdverse eventAffectAgitationAllosteric SiteAnhedoniaAntidepressive AgentsBackBiological AssayCause of DeathCell ProliferationCharacteristicsChemicalsChemistryChronicChronic DiseaseDataDevelopmentDimensionsDiseaseDrug KineticsEmotionsEtiologyExcretory functionFRAP1 geneFoundationsGlutamatesHealth Care CostsHippocampus (Brain)HumanIn VitroIncomeInterdisciplinary StudyKetamineLaboratoriesLeadMajor Depressive DisorderMediatingMedicalMetabolismMetabotropic Glutamate ReceptorsN-Methyl-D-Aspartate ReceptorsNational Institute of Mental HealthNeurobiologyNeuronsOralPatientsPharmaceutical PreparationsPlayPositioning AttributePrevalenceProductivityPropertyProsencephalonRecurrenceReportingResearch Domain CriteriaResistanceRewardsRodentRodent ModelRoleSelective Serotonin Reuptake InhibitorSeriesSexual DysfunctionSirolimusSiteSuicideSwimmingSymptomsSystemTail SuspensionTestingTherapeutic EffectToxic effectTreatment EfficacyTreatment outcomeabsorptionbehavioral studycompliance behaviorcostdesigndrug discoveryexperimental studygastrointestinal symptomhigh riskin vitro Assayin vivoin vivo Modelinhibitor/antagonistinnovationnervous system disorderneural circuitneuropsychiatric disorderneuropsychiatrynovelpreclinical studyprogramspublic health relevancereceptorresponsereward processingsmall moleculetooltransmission processtreatment responsetreatment-resistant depression
项目摘要
DESCRIPTION (provided by applicant): This R01 application entitled "Lead Optimization of Novel mGlu2 Negative Allosteric Modulators" is in response to PAR-13-048 "Drug Discovery for Nervous System Disorders". Major depressive disorder (MDD) is a serious disorder with an estimated lifetime prevalence of 19% and a societal cost >$83 billion a year in the USA. As with many other neuropsychiatric disorders, MDD is characterized by debilitating deficits in reward processing and dysfunctional neural circuitries mediating reward. Unfortunately, ~30-50% of patients suffer from treatment resistant depression (TRD) and do not respond to currently available antidepressants. Hence, there is a critical unmet need to develop effective therapeutics. Accumulating evidence suggests that the glutamatergic system may play an important role in the etiology, neurobiology, and potential management of reward processing deficits (RPDs). For example, group II metabotropic glutamate receptor (mGlu2 and mGlu3) antagonists have rapid and long-lasting antidepressant-like effects in multiple rodent tests of antidepressant activity. Antagonism of mGlu2/3 also increases neuronal proliferation in the hippocampus, an effect hypothesized to mediate antidepressant activity. However, it remains unclear whether group II mGlu antagonists may be effective for the management of RPDs that are resistant to current antidepressant medications. In the last decade, we have focused on developing small molecule group II mGlu allosteric modulators, which interact at less conserved allosteric sites topographically distinct from the mGlu orthosteric (glutamate) site. We have developed both lead and back-up series of mGlu2 negative allosteric modulators (NAMs) that are ready for full-scale chemistry optimization to provide compounds for suitable for behavioral studies. Thus, the overall objective of this project is to develop orally active mGlu2 NAMs for advanced in vivo proof-of-concept studies for the treatment of RPDs. Our Specific Aims are: 1) Design and synthesize optimized mGlu2 NAMs that are orally active in vivo; 2) Assess the potency and selectivity of mGlu2 NAMs in relevant in vitro assays; 3) Evaluate novel small molecule mGlu2 NAMs using in vitro ADME/T and in vivo pharmacokinetic (PK) assays; and 4) Characterize lead mGlu2 NAM probes in rodent in vivo models of antidepressant activity, anhedonia, and reward responsiveness. The mGlu2-selective NAMs generated will provide powerful tools for testing the role of mGlu2 in vivo. We are uniquely positioned to develop potent and selective small molecule mGlu2 NAMs with excellent PK properties for in vivo proof-of-concept studies, prior to the initiation of IND enabling studies. This multidisciplinary research program has the potential for significant scientific and medical impact by contributing to the discovery of new medications for neuropsychiatric disorders characterized by RPDs.
描述(由申请人提供):本R 01申请题为“新型mGlu 2负变构调节剂的先导优化”,是对PAR-13-048“神经系统疾病药物发现”的回应。重度抑郁症(MDD)是一种严重的疾病,在美国估计终生患病率为19%,每年的社会成本> 830亿美元。与许多其他神经精神疾病一样,MDD的特征是奖励处理中的衰弱缺陷和介导奖励的神经回路功能障碍。不幸的是,约30-50%的患者患有难治性抑郁症(TRD),并且对目前可用的抗抑郁药没有反应。因此,存在开发有效治疗剂的关键未满足的需求。越来越多的证据表明,脑电能系统可能在奖赏加工缺陷(RPDs)的病因学、神经生物学和潜在管理中发挥重要作用。例如,II组代谢型谷氨酸受体(mGlu 2和mGlu 3)拮抗剂在抗抑郁活性的多种啮齿动物试验中具有快速和持久的抗抑郁样作用。mGlu 2/3的拮抗作用还增加海马中的神经元增殖,这是一种假设介导抗抑郁活性的效应。然而,目前尚不清楚II组mGlu拮抗剂是否可有效治疗对当前抗抑郁药物耐药的RPD。在过去的十年中,我们一直专注于开发小分子II组mGlu变构调节剂,其在与mGlu正构(谷氨酸)位点在地形上不同的不太保守的变构位点相互作用。我们已经开发了mGlu 2负变构调节剂(NAM)的先导和备用系列,这些系列已准备好进行全面的化学优化,以提供适合行为研究的化合物。因此,本项目的总体目标是开发口服活性mGlu 2 NAM,用于治疗RPD的先进体内概念验证研究。我们的具体目标是:1)设计和合成在体内具有口服活性的优化的mGlu 2 NAM; 2)在相关的体外测定中评估mGlu 2 NAM的效力和选择性; 3)使用体外ADME/T和体内药代动力学(PK)测定来评估新型小分子mGlu 2 NAM;以及4)在抗抑郁活性、快感缺乏和奖赏响应性的啮齿动物体内模型中表征前导mGlu 2 NAM探针。产生的mGlu 2选择性NAM将为测试mGlu 2在体内的作用提供有力的工具。在IND启动研究之前,我们具有独特的优势,可以开发具有优异PK特性的强效和选择性小分子mGlu 2 NAM,用于体内概念验证研究。这个多学科的研究项目有可能通过发现以RPD为特征的神经精神疾病的新药物来产生重大的科学和医学影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicholas David Cosford其他文献
Nicholas David Cosford的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicholas David Cosford', 18)}}的其他基金
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder
用于阿片类药物使用障碍的双 mGlu2/3 正变构调节剂的表征、优化和开发
- 批准号:
10544440 - 财政年份:2022
- 资助金额:
$ 78.52万 - 项目类别:
Lead optimization of Novel mGlu2 Negative Allosteric Modulators
新型 mGlu2 负变构调节剂的先导化合物优化
- 批准号:
9029750 - 财政年份:2016
- 资助金额:
$ 78.52万 - 项目类别:
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN
FASN 硫酯酶结构域新型抑制剂的先导化合物优化
- 批准号:
9090093 - 财政年份:2014
- 资助金额:
$ 78.52万 - 项目类别:
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN
FASN 硫酯酶结构域新型抑制剂的先导化合物优化
- 批准号:
8768420 - 财政年份:2014
- 资助金额:
$ 78.52万 - 项目类别:
Lead Optimization of Novel Inhibitors of Tissue Non-specific Alkaline Phosphatase
新型组织非特异性碱性磷酸酶抑制剂的先导化合物优化
- 批准号:
8579764 - 财政年份:2013
- 资助金额:
$ 78.52万 - 项目类别:
Lead Optimization of Novel Inhibitors of Tissue Non-specific Alkaline Phosphatase
新型组织非特异性碱性磷酸酶抑制剂的先导化合物优化
- 批准号:
8727436 - 财政年份:2013
- 资助金额:
$ 78.52万 - 项目类别:
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes
鉴定 CRF 结合蛋白和 CRF 受体复合物的化学调节剂
- 批准号:
8514550 - 财政年份:2010
- 资助金额:
$ 78.52万 - 项目类别:
Group II mGluR antagonists and negative modulators in depression
II 组 mGluR 拮抗剂和负调节剂治疗抑郁症
- 批准号:
8146176 - 财政年份:2010
- 资助金额:
$ 78.52万 - 项目类别:
相似国自然基金
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
- 批准号:22007039
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
- 批准号:
- 批准年份:2019
- 资助金额:10.0 万元
- 项目类别:省市级项目
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
- 批准号:21372217
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
- 批准号:21172061
- 批准年份:2011
- 资助金额:30.0 万元
- 项目类别:面上项目
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
- 批准号:21176225
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
- 批准号:81072511
- 批准年份:2010
- 资助金额:31.0 万元
- 项目类别:面上项目
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
- 批准号:30660215
- 批准年份:2006
- 资助金额:21.0 万元
- 项目类别:地区科学基金项目
相似海外基金
CAREER: Highly Rapid and Sensitive Nanomechanoelectrical Detection of Nucleic Acids
职业:高度快速、灵敏的核酸纳米机电检测
- 批准号:
2338857 - 财政年份:2024
- 资助金额:
$ 78.52万 - 项目类别:
Continuing Grant
Lipid nanoparticle-mediated Inhalation delivery of anti-viral nucleic acids
脂质纳米颗粒介导的抗病毒核酸的吸入递送
- 批准号:
502577 - 财政年份:2024
- 资助金额:
$ 78.52万 - 项目类别:
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 78.52万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 78.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 78.52万 - 项目类别:
Continuing Grant
Integrated understanding and manipulation of hypoxic cellular functions by artificial nucleic acids with hypoxia-accumulating properties
具有缺氧累积特性的人工核酸对缺氧细胞功能的综合理解和操纵
- 批准号:
23H02086 - 财政年份:2023
- 资助金额:
$ 78.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 78.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 78.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 78.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthetic analogues based on metabolites of omega-3 fatty acids protect mitochondria in aging hearts
基于 omega-3 脂肪酸代谢物的合成类似物可保护衰老心脏中的线粒体
- 批准号:
477891 - 财政年份:2023
- 资助金额:
$ 78.52万 - 项目类别:
Operating Grants